MATTHEW MARX: Open Payments
NPI 1972185221 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,256 in 43 payments from 23 companies in 2025. Trend: 2023 $299 · 2024 $220 · 2025 $1,256
Food & beverage: $1,160Education: $96
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 3 | $340 |
| Pharmacosmos Therapeutics Inc. | 4 | $155 |
| Incyte Corporation | 3 | $108 |
| AstraZeneca Pharmaceuticals LP | 4 | $78 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Eisai Inc. | 3 | $61 |
| Novartis Pharmaceuticals Corporation | 3 | $61 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $48 |
| GENZYME CORPORATION | 2 | $35 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
Products named: Trodelvy, MONOFERRIC, JAKAFI, Enhertu, Lenvima, Nubeqa, EPKINLY, FOTIVDA.
Industry payments across PA — which companies pay providers there.
